N

Neumora Therapeutics Inc
NASDAQ:NMRA

Watchlist Manager
Neumora Therapeutics Inc
NASDAQ:NMRA
Watchlist
Price: 2.035 USD -4.46%
Market Cap: $335.3m

Neumora Therapeutics Inc
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Neumora Therapeutics Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
N
Neumora Therapeutics Inc
NASDAQ:NMRA
Research & Development
-$200.9m
CAGR 3-Years
-53%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Research & Development
-$14.7B
CAGR 3-Years
-1%
CAGR 5-Years
-4%
CAGR 10-Years
-5%
Bristol-Myers Squibb Co
NYSE:BMY
Research & Development
-$9.7B
CAGR 3-Years
-1%
CAGR 5-Years
-2%
CAGR 10-Years
-7%
Pfizer Inc
NYSE:PFE
Research & Development
-$10.1B
CAGR 3-Years
6%
CAGR 5-Years
-4%
CAGR 10-Years
-2%
Merck & Co Inc
NYSE:MRK
Research & Development
-$15.5B
CAGR 3-Years
-10%
CAGR 5-Years
-10%
CAGR 10-Years
-8%
Eli Lilly and Co
NYSE:LLY
Research & Development
-$12.6B
CAGR 3-Years
-21%
CAGR 5-Years
-17%
CAGR 10-Years
-11%
No Stocks Found

Neumora Therapeutics Inc
Glance View

Market Cap
335.3m USD
Industry
Pharmaceuticals

In the bustling world of biopharmaceuticals, Neumora Therapeutics Inc. carves a unique path through the intricacies of neuroscience, specializing in precision medicines for brain diseases. Founded on the convergence of a deep understanding of neurological disorders and cutting-edge data science, Neumora's mission centers around developing targeted therapies that offer hope and clarity to those grappling with complex mental health issues. The company harnesses an impressive integration of human data insights, machine learning tools, and novel biomarker technologies to identify and validate new therapeutic targets. This strategic approach allows Neumora to streamline the drug discovery and development process, ensuring a more precise alignment between therapeutic interventions and the specific needs of patient subtypes. Monetization for Neumora emerges through strategic collaborations, partnerships, and potential commercial sales of its approved therapies. By forming alliances with research institutions and pharmaceutical giants, the company not only enhances its R&D capabilities but also secures vital funding to propel its clinical programs. Furthermore, Neumora's business model may encompass licensing deals, allowing it to monetize its technology and intellectual properties, including proprietary biomarkers and AI-driven discovery platforms. As drug candidates advance through clinical trials and towards regulatory approval, Neumora positions itself to capture market share by addressing unmet needs in the neurology therapeutic landscape, offering innovative solutions in an industry ripe for disruption.

NMRA Intrinsic Value
0.151 USD
Overvaluation 93%
Intrinsic Value
Price
N

See Also

What is Neumora Therapeutics Inc's Research & Development?
Research & Development
-200.9m USD

Based on the financial report for Dec 31, 2024, Neumora Therapeutics Inc's Research & Development amounts to -200.9m USD.

What is Neumora Therapeutics Inc's Research & Development growth rate?
Research & Development CAGR 3Y
-53%

Over the last year, the Research & Development growth was -41%. The average annual Research & Development growth rates for Neumora Therapeutics Inc have been -53% over the past three years .

Back to Top